Sponsors

Genomic test for tumour grade

Ipsogen, a company that markets molecular diagnostics assays for leukaemia, has launched MapQuant DxT Genomic Grade. The new assay is a molecular diagnostic test for breast tumour grade, which is an indicator of tumour proliferation, metastasis risk and response to chemotherapy.

Histological tumour grading is considered to be a decision factor in most national and international guidelines on breast cancer treatment. While it is generally recommended that high-grade breast cancer be treated with chemotherapy because it is chemosensitive, most low-grade breast tumours have a good prognosis and often do not respond to chemotherapy.

www.ipsogen.com

Latest Issues

BAC Annual Scientific Meeting 2025

Online
20 November, 2025

UK NEQAS for Microbiology Annual Scientific Meeting

The Royal National Hotel, 38 – 51 Bedford Way, London, WC1H 0DG
28 November, 2025

Introduction to bone marrow trephine

Online
9 December, 2025